Projects › SURGISTT 2
Central question 10: What is the role of surgery to cure?
Hypothesis
Metastatic GIST cannot be cured without surgery or another effective local therapy. Imatinib shrinks most metastases, but some tumor cells always survive the drug, and resistance grows out of them. If what remains after the best response can be removed, fewer cells are left to become resistant. Whether that translates into longer control or longer life has never been tested in a randomized trial, and the two trials that tried to (in Europe and in China) closed early because too few patients agreed to be randomized.
Design
A registry of patients with metastatic GIST who responded to imatinib, with and without surgery of the residual disease. The two groups are compared as matched pairs, with the same mutation, the same extent of disease and the same depth of response; an instrumental-variable analysis, which uses the center's practice as the variable, is the alternative when matching leaves too few pairs. A sub-project surveys how practice varies between centers: who is offered surgery, when, and for which lesions.
What the registry records
- Mutation, sites and number of metastases at diagnosis
- CT images at four time points: baseline, best response on imatinib, after surgery, first progression
- Surgery: what was removed, completeness, complications
- Treatment lines, progression and survival
What makes it feasible
- Images and clinical information only: no samples, no extra visits
- Central reading of every scan, so that "resectable" means the same thing at every site
- A shared REDCap form and a central imaging platform (XNAT), hosted in Essen
- Open to sites inside and outside the European Economic Area
How a site takes part
- JoinSign the registry agreement and obtain local ethics approval; template documents are provided.
- IdentifyPatients treated for metastatic GIST with imatinib, with or without surgery of the residual disease.
- UploadPseudonymized CT scans at the four time points, and the clinical form in REDCap.
- ReadCentral reading of resectability at best response; the matched comparison follows.
Scientific board
- Fahima Dossa, MD, PhDCedars-Sinai Medical Center · Los Angeles, USA
- Prof. Alessandro Gronchi, MDFondazione IRCCS Istituto Nazionale dei Tumori · Milan, Italy
- Prof. Peter Hohenberger, MDUniversity Medical Center Mannheim, Heidelberg University · Mannheim, Germany
- Moritz Kaths, MD, MScUniversity Hospital Essen · Essen, Germany
- Prof. Chandrajit P. Raut, MD, MScBrigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School · Boston, USA
- Prof. Piotr Rutkowski, MD, PhDMaria Sklodowska-Curie National Research Institute of Oncology · Warsaw, Poland
- Prof. Jason K. Sicklick, MDUC San Diego · San Diego, USA
Sites
Activated sites and sites with activation pending: to be listed.
What comes next
The registry defines the limits and prerequisites for surgery in metastatic disease. Those definitions go into the surgical arm of the GISTT-RACE platform trial, and the registry patients become part of its growing control backbone.